Utilization of smoking-cessation pharmacotherapy among chronic obstructive pulmonary disease (COPD) and lung cancer patients

Current Medical Research and Opinion

Volumn 30, Issue 6, 2014, Pages 1043-1050

  Vaidya, Varun ^a   Hufstader Gabriel, Meghan ^b   Gangan, Nilesh ^a   Shah, Surbhi ^a   Bechtol, Robert ^a  

^a UNIVERSITY OF TOLEDO   (United States)

^b Office of Health Information Technology Adoption   (United States)

Author keywords

Chronic obstructive pulmonary disease; Disparities; Lung cancer; MEPS; Pharmacotherapy; Smoking cessation

Indexed keywords

AMFEBUTAMONE; CHLORDIAZEPOXIDE; DRUGS USED IN THE TREATMENT OF ADDICTION; NICOTINE GUM; NICOTINE PATCH; NON PRESCRIPTION DRUG; PRESCRIPTION DRUG; SMOKING CESSATION AGENT; UNCLASSIFIED DRUG; VARENICLINE;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CANCER PATIENT; CAUCASIAN; CHRONIC OBSTRUCTIVE LUNG DISEASE; EDUCATIONAL STATUS; ETHNIC DIFFERENCE; FEMALE; HEALTH CARE UTILIZATION; HEALTH DISPARITY; HEALTH INSURANCE; HISPANIC; HUMAN; INCOME; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICALLY UNINSURED; PREVALENCE; RETROSPECTIVE STUDY; SELF REPORT; SMOKING; SMOKING CESSATION; SMOKING CESSATION PROGRAM; LUNG NEOPLASMS; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SOCIAL ASPECTS AND RELATED PHENOMENA; STATISTICS AND NUMERICAL DATA; UNITED STATES; YOUNG ADULT;

ADULT; AGED; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; SOCIOLOGICAL FACTORS; TOBACCO USE CESSATION PRODUCTS; UNITED STATES; YOUNG ADULT;

EID: 84900806533     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.884493     Document Type: Article

References (39)

1. Mannino DM, Homa DM, Akinbami LJ, et al. Chronic obstructive pulmonary disease surveillance-United States, 1971-2000. Respir Care 2002;47:1184-99
2. Heron M. Deaths: leading causes for 2008. National vital statistics reports: from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System. 2012;60:1-94
3. The 2004 United States Surgeon General's Report: The health consequences of smoking. NSW Public Health Bulletin 2004;15:107
4. Koshiol J, Rotunno M, Consonni D, et al. Chronic obstructive pulmonary disease and altered risk of lung cancer in a population-based case-control study. PLoS One 2009;4:e7380
5. Brown DW, Croft JB, Greenlund KJ, et al. Trends in hospitalization with chronic obstructive pulmonary disease-United States, 1990-2005. COPD 2010;7:59-62
6. Parsons A, Daley A, Begh R, et al. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-Analysis. BMJ 2010;340:b5569
7. Yohannes AM. Lung cancer in patients with chronic obstructive pulmonary disease is a double blow. Expert Rev Respir Med 2012;6:3-6
8. Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005;142:233-9
9. Wu J, Sin DD. Improved patient outcome with smoking cessation: when is it too late? Int J Chron Obstruct Pulmon Dis 2011;6:259-67
10. Cataldo JK, Dubey S, Prochaska JJ. Smoking cessation: an integral part of lung cancer treatment. Oncology 2010;78:289-301
11. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Criti Care Med 2013;187:347-65
12. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-46
13. Hughes J, Stead L, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2004;4:CD000031
14. Cummings KM, Hyland A. Impact of nicotine replacement therapy on smoking behavior. Annu Rev Publ Health 2005;26:583-99
15. Cox LS, Africano NL, Tercyak KP, et al. Nicotine dependence treatment for patients with cancer. Cancer 2003;98:632-44
16. Jimenez-Ruiz CA, Riesco Miranda JA, Altet Gomez N, et al. Treatment of smoking in smokers with chronic obstructive pulmonary disease. Archivos de Bronconeumologia 2013;49:354-63
17. Vaidya V, Partha G, Howe J. Utilization of preventive care services and their effect on cardiovascular outcomes in the United States. Risk Manag Healthc Pol 2011;4:1-7
18. Conner NE. Predictive factors of hospice use among Blacks: applying Andersen's Behavioral Model. Am J Hospice Palliative Care 2012;29:368-74
19. Moczygemba LR, Barner JC, Lawson KA, et al. Impact of telephone medication therapy management on medication and health-related problems, medication adherence, and Medicare Part D drug costs: a 6-month follow up. Am J Geriatr Pharmacother 2011;9:328-38
20. Unni E, Farris KB. Determinants of different types of medication non-Adherence in cholesterol lowering and asthma maintenance medications: a theoretical approach. Patient Educ Counsel 2011;83:382-90
21. Almagro P, Castro A. Helping COPD patients change health behavior in order to improve their quality of life. Int J COPD 2013;8:335-45
22. Jyrkkio S, Bostrom P, Minn H. [Smoking and cancer-what are the benefits of cessation?]. Duodecim; laaketieteellinen aikakauskirja 2012;128: 1081-7
23. Thun MJ, Carter BD, Feskanich D, et al. 50-year trends in smoking-related mortality in the United States. N Engl J Med 2013;368:351-64
24. Laniado-Laborin R. Smoking cessation intervention: an evidence-based approach. Postgrad Med 2010;122:74-82
25. Patel DR, Feucht C, Reid L, et al. Pharmacologic agents for smoking cessation: a clinical review. Clinical Pharmacol Advances Applications 2010;2:17-29
26. Hopenhayn C, Christian WJ, Christian A, et al. Factors associated with smoking abstinence after diagnosis of early stage lung cancer. Lung Canc 2013;80:55-61
27. Cooley ME, Sarna L, Kotlerman J, et al. Smoking cessation is challenging even for patients recovering from lung cancer surgery with curative intent. Lung Canc 2009;66:218-25
28. Park ER, Japuntich SJ, Rigotti NA, et al. A snapshot of smokers after lung and colorectal cancer diagnosis. Cancer 2012;118: 3153-64
29. Thabane M, Group CW. Smoking cessation for patients with chronic obstructive pulmonary disease (COPD): an evidence-based analysis. Ontario Health Tech Assess 2012;12:1-50
30. Tilea L, Postolache P, Lica F, et al. Ethics and smoking cessation: should the medical treatment be a freewill choice or a mandatory issue for hospitalized COPD patients? Chest 2012;142:1089A
31. Waidmann TA, Rajan S. Race and ethnic disparities in health care access and utilization: an examination of state variation. Med Care Res Rev 2000;57(Suppl 1):55-84
32. Vaidya V, Holiday-Goodman M, Pinto S. Demographic disparities in patient-reported use of inhaled corticosteroids among patients with persistent asthma. J Asthma Allergy 2010;3:101-6
33. Vaidya V, Peeters MJ, Partha G, et al. Evaluating the association between type of prescription drug plan and asthma patients' use of controller medications. J Pharmaceut Health Serv Res 2012;3:65-9
34. Kandel DB, Kiros G-E, Schaffran C, et al. Racial/ethnic differences in cigarette smoking initiation and progression to daily smoking: a multilevel analysis. Am J Publ Health 2004;94:128-35
35. Covey LS, Botello-Harbaum M, Glassman AH, et al. Smokers' response to combination bupropion, nicotine patch, and counseling treatment by race/ethnicity. Ethn Dis 2008;18:59-64
36. Health, United States, 2009: With Special Feature on Medical Technology. Hyattsville MD, 2010. Available at: http://www.cdc.gov/nchs/data/hus/hus09.pdf
37. Fiore MC, Goplerud E, Schroeder SA. The Joint Commission's New Tobacco-Cessation Measures-Will Hospitals Do the Right Thing? N Engl J Med 2012;366:1172-4
38. Buck DJ, Richmond RL, Mendelsohn CP. Cost-effectiveness analysis of a family physician delivered smoking cessation program. Prev Med 2000;31:641-8
39. Centers for Medicare and Medicaid Services. Available at: http:///www.cms.gov/Regulations-And-Guidance/Legislation/EHRIncentivePrograms [Last accessed 5 September 2013]